The drug against obesity Zepbound, by Eli Lillyis now available in pharmacies in the United States and could be available for some insured customers at US$550 per month or half the retail price, the US pharmaceutical company reported on Tuesday.
The company makes this weight loss drug available to adults through its commercial savings card program, through which members with coverage can choose to pay as little as US$25 for a 1- or 3-month prescription.
Meanwhile, adults without commercial insurance can pay up to $550 for a one-month prescription.
The drug was approved in November, paving the way for a powerful new rival to Novo Nordisk’s Wegovy to address record obesity rates.
Lilly’s tirzepatide has been available as Mounjaro for type 2 diabetes since 2022 and was increasingly used for weight loss while anti-obesity approval was pending.
Source: Gestion
Ricardo is a renowned author and journalist, known for his exceptional writing on top-news stories. He currently works as a writer at the 247 News Agency, where he is known for his ability to deliver breaking news and insightful analysis on the most pressing issues of the day.
